SPA17 Antibody

What is SPA17 and where is it normally expressed?

SPA17 is a sperm surface zona pellucida binding protein that helps bind spermatozoa to the zona pellucida with high affinity. Under normal physiological conditions, SPA17 expression is primarily restricted to male reproductive tissues, specifically testis germ cells. It belongs to the cancer-testis antigens (CTAs) family, which is characterized by expression limited to male reproductive tissues in healthy individuals. This restricted expression pattern makes it particularly interesting as a potential therapeutic target . SPA17 might function in binding zona pellucida and carbohydrates, although some aspects of its function are still being investigated .

How can researchers detect SPA17 expression in tissue samples?

Detection of SPA17 in tissue samples is typically performed using immunohistochemistry (IHC-P) with specific anti-SPA17 antibodies. For optimal results, researchers should:

• Use validated rabbit polyclonal antibodies specific to SPA17 (such as those raised against recombinant full-length protein)

• Include appropriate positive controls (testicular tissue or known SPA17-expressing cancer lines like MDA-MB-231 for breast cancer studies)

• Include negative controls (normal breast tissue has been shown to lack SPA17 expression)

• Quantify expression using established scoring systems based on staining intensity and percentage of positive cells

When interpreting results, researchers should be aware that in studies of breast cancer tissues, SPA17 expression was detected in 27% of cancer samples while being completely absent in normal breast tissues, making it a potentially useful biomarker .

What are the key methodological considerations when using SPA17 antibodies?

When working with SPA17 antibodies, researchers should consider:

• Antibody validation: Confirm specificity using Western blot analysis in positive control cells (e.g., MDA-MB-231 breast cancer cells show high SPA17 expression) and negative control cells (e.g., MCF-7 breast cancer cells show minimal expression)

• Cross-reactivity: Evaluate potential cross-reactivity with related proteins, particularly when working with polyclonal antibodies

• Application-specific optimization: Different applications (Western blot, IHC-P) may require different antibody dilutions and sample preparation protocols

• Species compatibility: Verify that the selected antibody has been validated for your species of interest (mouse, rat, human)

• Sample preparation: For IHC applications, optimization of antigen retrieval methods is essential for accurate SPA17 detection

How is SPA17 expression altered in different cancer types?

SPA17 exhibits significant expression alterations across various cancer types:

• Breast cancer: Studies show SPA17 expression in 27% of breast cancer samples, with expression in ductal breast carcinoma in situ 2.20 times higher and in invasive ductal breast cancer 2.05 times higher than in normal breast tissues

• Molecular subtypes: Expression varies by breast cancer subtype, with highest expression in triple-negative (60%) and HER2-positive (45%) breast cancers

• Other cancers: SPA17 is abnormally expressed in multiple cancer types including melanoma, non-small cell lung cancer, ovarian cancer, and endometrial carcinoma

• Normal tissues: SPA17 expression is not detected in normal breast tissues and is limited in other normal tissues

This expression pattern makes SPA17 potentially valuable as both a diagnostic marker and therapeutic target, particularly for aggressive breast cancer subtypes.

What is the relationship between SPA17 expression and cancer metastasis?

Research has established a significant relationship between SPA17 expression and cancer metastasis:

When designing experiments to study this relationship, researchers should include both gain-of-function (overexpression) and loss-of-function (siRNA knockdown) approaches to comprehensively assess SPA17's impact on cell migration and invasion.

How does SPA17 influence the tumor microenvironment and immune response?

SPA17 expression has been linked to significant alterations in tumor immune microenvironment:

• Immune cell infiltration: SPA17 expression correlates with infiltration levels of various immune cells, including:

  • CD4+ and CD8+ T cells

  • Regulatory T cells (Tregs)

  • Cancer-associated fibroblasts (CAF)

  • Myeloid-derived suppressor cells (MDSC)

  • Natural killer T cells (NKT)

• Immune pathway activation: Gene Set Enrichment Analysis (GSEA) reveals that SPA17 expression is significantly associated with immune-activated hallmarks, including specific pathways and biological processes related to immune function

• Immunotherapy response: Perhaps most significantly for clinical applications, SPA17 expression can predict responses to immune checkpoint inhibitor therapy, including anti-PDL1 and anti-PD1 treatments in cancer patients

Researchers investigating SPA17's immune-related functions should employ comprehensive immune cell profiling techniques alongside SPA17 expression analysis to fully characterize these relationships.

How can researchers use SPA17 antibodies to study epitope-specific responses?

Understanding SPA17 epitopes is crucial for both basic research and potential therapeutic applications:

• Dominant epitopes: Studies in vasectomized men show that autoantibodies against SPA17 predominantly target two linear B cell epitopes:

  • Amino acids 4-19

  • Amino acids 118-127

• Recombinant vs. native epitopes: Importantly, these epitopes differ from (but partially overlap with) those recognized in recombinant SPA17 protein:

  • Recombinant protein epitopes: amino acids 52-79 and 124-136

  • Native protein epitopes: amino acids 4-19 and 118-127

• Research applications: When developing experimental approaches:

  • Use epitope mapping to determine which regions of SPA17 are recognized by different antibodies

  • Consider epitope-specific antibodies when studying functional domains

  • For immunotherapy research, focus on epitopes that generate strong immune responses

This information is particularly relevant for researchers developing targeted therapies or diagnostic tools based on SPA17.

What experimental approaches can best evaluate SPA17's role in cancer progression?

To effectively study SPA17's role in cancer progression, researchers should consider these methodological approaches:

• Cell line models:

  • Use paired cell lines with differential SPA17 expression (e.g., MCF-7 with low expression vs. MDA-MB-231 with high expression)

  • Generate stable SPA17-overexpressing cell lines through transfection with SPA17 cDNA

  • Develop SPA17-knockdown models using siRNA or CRISPR-Cas9 technology

• Functional assays:

  • Migration assays (Transwell): Quantify cell migration with and without SPA17 expression

  • Invasion assays: Assess the ability of cells to penetrate extracellular matrix

  • Proliferation assays: Evaluate whether SPA17 affects cell growth rates

  • In vivo metastasis models: Examine SPA17's impact on tumor spread in animal models

• Molecular mechanism investigation:

  • Identify SPA17-interacting proteins through co-immunoprecipitation

  • Analyze downstream signaling pathways affected by SPA17 expression

  • Evaluate changes in epithelial-mesenchymal transition (EMT) markers

Research has shown that while SPA17 significantly impacts migration and invasion of breast cancer cells, it does not appear to affect their proliferation, suggesting a specific role in metastatic processes .

How can SPA17 antibodies be used to predict immunotherapy response?

SPA17 has emerged as a potential biomarker for immunotherapy response:

• Predictive value: Studies demonstrate that SPA17 expression can significantly predict responses to immune checkpoint inhibitors, specifically anti-PDL1 and anti-PD1 therapies

• Research methodology:

  • Correlate SPA17 expression levels (determined by immunohistochemistry) with patient response to immunotherapy

  • Use multivariate analysis to determine whether SPA17 is an independent predictor when controlling for other known factors

  • Combine SPA17 with other biomarkers to develop comprehensive predictive models

• Laboratory approaches:

  • Develop standardized assays for SPA17 quantification in clinical samples

  • Create tissue microarrays from immunotherapy trial samples to assess SPA17's predictive value

  • Establish threshold values for "high" versus "low" SPA17 expression in relation to therapy response

This application represents one of the most clinically relevant uses of SPA17 antibodies in the current immunotherapy landscape.

What is the potential of SPA17 as a therapeutic target in cancer?

SPA17's restricted normal tissue expression and prevalence in certain cancers make it an attractive therapeutic target:

• Immunogenicity: SPA17 has been confirmed to be immunogenic, as evidenced by:

  • Natural autoantibody production in vasectomized men

  • The ability to generate SPA17-specific, HLA class I-restricted, cytotoxic T lymphocytes capable of efficiently killing breast cancer cells

• Therapeutic approaches being explored:

  • Adoptive T cell therapy (ACT) targeting SPA17

  • Development of SPA17-based cancer vaccines

  • Dendritic cell-based immunotherapy (e.g., umbilical cord blood-derived dendritic cells modulated for SPA17 expression)

  • Antibody-based targeting strategies

• Experimental validation:

  • Previous studies confirmed that SPA17 antibodies can effectively inhibit the growth of human ovarian cancer cells SKOV-3

  • Dendritic cells expressing SPA17 induced antigen-specific anti-tumor immunity against SPA17-positive non-small cell lung cancer

Researchers working on SPA17-targeted therapies should consider both its expression pattern across cancer types and its specific epitopes that generate immune responses.

How can researchers address variability in reported SPA17 expression rates?

Studies report different SPA17 expression rates in cancer tissues, which researchers must carefully interpret:

• Methodological differences:

  • The study by Gjerstorff and Ditzel reported 12% SPA17 expression in breast cancer, lower than the 27% found in more recent research

  • These differences may arise from detection methods, antibody specificity, or patient selection criteria

• Approaches to reconcile differences:

  • Standardize detection protocols and scoring systems

  • Consider molecular subtyping in analyses (expression rates vary significantly by subtype)

  • Account for sample size and patient population characteristics

  • Evaluate antibody specificity and potential cross-reactivity

• Research design recommendations:

  • Include balanced representation of molecular subtypes

  • Use multiple detection methods (IHC, PCR, Western blot)

  • Employ tissue microarrays to minimize technical variability

  • Include clear positive and negative controls

The higher expression rate (27%) observed in recent studies may be due to deliberate balancing of molecular subtypes in the patient cohort, as triple-negative (60%) and HER2-positive (45%) subtypes show much higher SPA17 expression than luminal subtypes .

What controls are essential when designing experiments involving SPA17?

Proper controls are critical for generating reliable data in SPA17 research:

• Essential positive controls:

  • Testicular tissue (natural site of SPA17 expression)

  • Known SPA17-expressing cancer cell lines (e.g., MDA-MB-231 for breast cancer studies)

  • Recombinant SPA17 protein (for antibody validation)

• Essential negative controls:

  • Normal breast tissue (shown to lack SPA17 expression)

  • SPA17-negative cell lines (e.g., MCF-7 shows minimal expression)

  • SPA17-knockdown cells (using siRNA or CRISPR)

• Experimental validation approaches:

  • Use multiple antibodies targeting different SPA17 epitopes

  • Confirm protein expression using both Western blot and immunohistochemistry

  • Validate functional findings using both overexpression and knockdown approaches

  • Include isotype control antibodies in immunologic assays

These controls help ensure that observed effects are specifically related to SPA17 and not artifacts of experimental design or antibody cross-reactivity.